- Reuters•2 hours ago
An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday. Interim results from the multi-center trial for 50 patients with acute lymphoblastic leukemia whose cancer returned or did not respond to other treatment, showed that 41 were disease-free three months after treatment with the drug, called CTL019. Novartis estimated that 60 percent of those responders were relapse-free after six months.
- Barrons.com•23 hours ago
Click here to see our favorite 2017 stocks. Equity investors face a big choice for 2017. Bet on appreciated “Trump” stocks in the hopes of a stronger economy, or focus on more-defensive sectors. Since ...
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||67.66 x 100|
|Ask||69.99 x 100|
|Day's Range||67.57 - 68.30|
|52 Week Range||67.28 - 88.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.04|
|Dividend & Yield||2.72 (4.01%)|
|1y Target Est||N/A|